Exploiting developments in nanotechnology for the preferential delivery of platinum-based anti-cancer agents to tumours: targeting some of the hallmarks of cancer

Parker, J.; Ude, Ziga; Marmion, Celine J.

doi:10.1039/c5mt00181a

Cited by 53 publications

(30 citation statements)

References 172 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current treatment is based on different types of combinations in chemotherapy and exterior ray radiation has unsuccessful to enhance existence, resulting in an average existence rate of 4 to 6 months and less than 20% existence level in 12 months. Here are therefore convincing explanations for developing a new theranostics approach for initial nding and e cient ATC treatment [16][17][18][19].…”

Section: Introductionmentioning

confidence: 92%

Gadollium Nanoparticles Delivery for Low Intensity Focused Ultrasound Diagnosis Ablation of Thyroid Cancer Therapy

Qi¹,

Zhu²,

Wang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Chemotherapeutic efficacy can be significantly developed nanotheranostics systems of drug delivery in tumor cells. In this work, we have demonstrated that the self-assembled by C225 conjugates Gd-PFH-NPs (C-Gd-PFH-NPs) for low intensity focused ultrasound diagnosis ablation of thyroid cancer treatment. C-Gd-PFH-NPs have shown excellent stability in PBS. Transmission electron microscopy (TEM) images also exposed the effective construction of C-Gd-PFH-NPs with commonly spherical sized assemblies. The incubation of the C625 thyroid carcinoma with C-Gd-PFH-NPs triggers apoptosis, which was confirmed by the flowcytometry analysis. The C-Gd-PFH-NPs, with remarkably displays the potent antitumor efficacy in a human C625 thyroid carcinoma xenografts. A histopathological result reveals that precisely achieved to additional confirm these outcomes. Further, we successfully examined the efficiency of C-Gd-PFH-NPs when used the thyroid carcinoma low intensity focused ultrasound diagnosis imaging (LIFUS) in vivo. These findings clearable for LIFUS agents with high performing image and different therapeutic purpose will have extensive possible for the future biomedical purposes.

show abstract

Section: Introductionmentioning

confidence: 92%

Gadollium Nanoparticles Delivery for Low Intensity Focused Ultrasound Diagnosis Ablation of Thyroid Cancer Therapy

Qi¹,

Zhu²,

Wang³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Moreover, even the clinical application of the successful ones has been compromised by flaws that are associated with cisplatin. 17 The urgent need to develop platinumbased complexes that can form DNA adducts that are qualitatively and quantitatively different from those already established for cisplatin and its analogues strongly supports the hypothesis that an active trans-platinum complex may have a different spectrum of activity. An attempt to develop trans-platinum with cytotoxic activity led Farrell et al 13,18 to incorporate bulky amine ligands, such as aromatic N-donor and other heterocycles, into the structure of transplatin.…”

Section: Introductionmentioning

confidence: 96%

“…Despite a large number of these cis‐configured compounds reported every year, only a handful of them has made it to clinical trials 15‐16 . Moreover, even the clinical application of the successful ones has been compromised by flaws that are associated with cisplatin 17 . The urgent need to develop platinum‐based complexes that can form DNA adducts that are qualitatively and quantitatively different from those already established for cisplatin and its analogues strongly supports the hypothesis that an active trans ‐platinum complex may have a different spectrum of activity.…”

Section: Introductionmentioning

confidence: 99%

An investigation of comparative substitution behavior of bifunctional trans‐platinum(II) complexes with symmetric and asymmetric alkylamine ligands

Olusegun

Reddy

Jaganyi

2020

Int J of Chemical Kinetics

View full text Add to dashboard Cite

This study was undertaken to investigate the comparative substitution behavior of mononuclear trans-platinum(II) complexes with symmetric and asymmetric amine ligands. The rate of substitution of the aqua moeities from the complexes trans-[Pt(NH 3) 2 (H 2 O) 2 ](ClO 4) 2 (tPt), trans-[Pt(NH 3)(NH 2 C 2 H 5)(H 2 O) 2 ] (ClO 4) 2 (tPt2H 2 O), trans-[Pt(NH 3)(NH 2 C 3 H 7)(H 2 O) 2 ](ClO 4) 2 (tPt3H 2 O), [trans-Pt(OH 2) 2 (NH 2 CH 3) 2 ](ClO 4) 2 (tPtM), and [trans-Pt(OH 2) 2 {NH 2 CH(CH 3) 2 } 2 ] (ClO 4) 2 (tPtR), by three nucleophiles, namely thiourea (TU), 1,3-dimethylthiourea (DMTU), and 1,1,3,3-tetramethylthiourea (TMTU) was studied under pseudo-first-order conditions as a function of concentration and temperature by stopped-flow spectrophotometry. All the substitution reactions of each of the trans-platinum(II) complexes proceeds by a stepwise mechanism involving rate-determining substitution of the first aqua ligand followed by a fast second substitution step, without any intermediates formed. The reactions were second order overall (rate = k obs [complex] where k obs = k 2 [nucleophile]), first order in both [complex] and [nucleophile]. The reactivity of the complexes was essentially governed by both steric and electronic factors. Comparing the second-order rate constants for the substitution reactions of the mononuclear diaqua trans-platinum(II) complexes with the thiourea-based nucleophiles, the observed trend follows: tPt > tPt2H 2 O > tPtM > tPt3H 2 O > tPtR. This reactivity trend is consistent with the pK a values obtained for the first deprotonation step. The reactivity of the nucleophiles with the complexes decreases with an increase in steric demand in the following order: TU > DMTU > TMTU. The low positive values of activation enthalpy and large negative values of activation entropy indicate an associative mechanism of substitution in all the complexes. The computational modeling using density functional theory calculations was employed to provide theoretical interpretation of kinetic data.

show abstract

“…The pre-clinical performance of the GEM is extensively compromised via essential obstacles including the blood flow rate of half-lifer period, quick deactivations and defecations, establishment of the drug resistances, and potentially serves as a side effect. Consequently, there is an essential motivation for the increased net easy but efficiency methods to completely attach GEM, which can widen the efficacy of this drug type for the managements of demoralizing the thyroid cancer (Zhang et al., 2013 ; Delplace et al., 2014 ; Kim et al., 2015 ; Parker et al., 2016 ).…”

Section: Introductionmentioning

confidence: 99%

Precise engineering of Gemcitabine prodrug cocktails into single polymeric nanoparticles delivery for metastatic thyroid cancer cells

Liu

Han²,

Liu

et al. 2020

Drug Delivery

View full text Add to dashboard Cite

GLOBOCAN estimates 36 types of cancers in 185 countries based on the incidence, mortality, and prevalence in the year 2019. Nowadays, chemotherapy is the most widely used cancer treatment among immune, radio, hormone, and gene therapies. Here, we describe a very simple yet cost-effective approach that synergistically combines drug reconstitution, supramolecular nano-assembly, and tumor-specific targeting to address the multiple challenges posed by the delivery of the chemotherapeutic Gemcitabine (GEM) drug. The GEM prodrugs were gifted to impulsively self-assemble into excellent steady nanoparticles size on covalent conjugation of linoleic acid hydrophobic through amide group with $100 nm. Newly synthesized GEM-NPs morphology was confirmed by various electron microscopic techniques. After successful synthesis, we have evaluated the anticancer property of GEM and GEM-NPs against B-CPAP (papillary thyroid carcinoma) and FTC-133 (human follicular thyroid carcinoma) cancer cell lines. Further studies such as AO-EB (acridine orange-ethidium bromide), nuclear staining and flow cytometry analyses on cell death mechanism signified that the cytotoxicity was associated with apoptosis in thyroid cancer cells. GEM-NPs show excellent biocompatibility compared to GEM. The present study explained that GEM-NPs as a safe and hopeful strategy for chemotherapeutics of thyroid cancer therapy and deserve for further clinical evaluations.

show abstract

Exploiting developments in nanotechnology for the preferential delivery of platinum-based anti-cancer agents to tumours: targeting some of the hallmarks of cancer

Cited by 53 publications

References 172 publications

Gadollium Nanoparticles Delivery for Low Intensity Focused Ultrasound Diagnosis Ablation of Thyroid Cancer Therapy

Gadollium Nanoparticles Delivery for Low Intensity Focused Ultrasound Diagnosis Ablation of Thyroid Cancer Therapy

An investigation of comparative substitution behavior of bifunctional trans‐platinum(II) complexes with symmetric and asymmetric alkylamine ligands

Precise engineering of Gemcitabine prodrug cocktails into single polymeric nanoparticles delivery for metastatic thyroid cancer cells

Contact Info

Product

Resources

About